Loading
Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.
MKI67 encodes a large nuclear protein expressed through the active phases of the cell cycle and absent in resting (G0) cells. The Ki-67 labelling index by immunohistochemistry (antibody MIB-1 on paraffin sections) grades neuroendocrine tumours in the WHO classification and is read in breast cancer as a proliferation marker; the abemaciclib adjuvant approval of 2021 used a Ki-67 score of at least 20 percent as an entry criterion before the label was broadened in 2023. It is a readout, not a drug target: no approved medicine binds Ki-67.
In plain words · Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.
Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.
Ki-67 coats the surface of mitotic chromosomes and keeps them from clumping; its level rises through S, G2 and M phase and falls to nothing in quiescent cells, which is why the stained fraction tracks proliferation.
No product in this corpus aims at Ki-67 (MKI67) yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MKI67: RNA group enriched (bone marrow 44 nTPM, lymphoid tissue 49 nTPM); high antibody staining in 5 normal tissues; highest cancer staining stomach cancer (9 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Neuroendocrine tumours); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MKI67 tissue; Open Targets ENSG00000148773 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Schlueter et al, J. Cell Biol, 1993, "The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins". Source.
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Ki-67 coats the surface of mitotic chromosomes and keeps them from clumping; its level rises through S, G2 and M phase and falls to nothing in quiescent cells, which is why the stained fraction tracks proliferation.
RNA: group enriched (bone marrow 44 nTPM, lymphoid tissue 49 nTPM), detected in many normal tissues.
Medium: Breast, Cervix, Colon, Kidney, Placenta, Spleen, Testis, Vagina.
Medium only: carcinoid, glioma, renal cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"Ki-67" OR ABSTRACT:"Ki-67" OR TITLE:"MKI67" OR ABSTRACT:"MKI67" OR TITLE:"Ki67" OR ABSTRACT:"Ki67" OR TITLE:"MIB-1" OR ABSTRACT:"MIB-1" OR TITLE:"marker of proliferation Ki-67" OR ABSTRACT:"marker of proliferation Ki-67") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ki-67 (MKI67), not a curated reading list.
Shares CIViC and the tag biomarker-parent.
Shares CIViC and the tag biomarker-parent.
Shares CIViC and the tag biomarker-parent.
Shares Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers, CIViC, HR-positive / HER2-negative breast cancer and the tag biomarker-parent.
Shares Neuroendocrine tumour grade (Ki-67) and WHO classification, Ki-67 index (proliferation by IHC), Neuroendocrine tumours.
Shares Neuroendocrine tumour grade (Ki-67) and WHO classification, Neuroendocrine tumours.
Shares Ki-67 index (proliferation by IHC), Immunohistochemistry (IHC), HR-positive / HER2-negative breast cancer.
Shares Ki-67 index (proliferation by IHC), Immunohistochemistry (IHC), HR-positive / HER2-negative breast cancer.